IPCA Laboratories · NSE: IPCALAB · BSE: 524494

Q2 FY21 results · Jul–Sep 2020

IPCA Laboratories reported revenue from operations of ₹1,361.10 crore (up 6.0% from Q2 FY20) and net profit of ₹266.70 crore (up 37.8% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY21	Q2 FY20	YoY	Q1 FY21	QoQ
Revenue from operations	1,361.10	1,283.90	+6.0%	1,534.40	−11.3%
Other income	15.45	14.80	+4.4%	12.09	+27.8%
Total income	1,376.55	1,298.70	+6.0%	1,546.49	−11.0%
Profit before share of associates & JVs and tax	321.21	226.80	+41.6%	546.64	−41.2%
Share of profit/(loss) of associates & JVs	(1.92)	(1.37)		(1.07)
Net profit for the period	266.70	193.54	+37.8%	445.68	−40.2%
Attributable to shareholders of the company	267.07	193.07	+38.3%	446.13	−40.1%
EPS, basic (₹)	21.08	15.32	+37.6%	35.27	−40.2%
Net margin (%)	19.6	15.1		29.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY21	Q2 FY20	YoY	Q1 FY21	QoQ
Revenue from operations	1,297.77	1,212.56	+7.0%	1,485.25	−12.6%
Other income	15.00	14.33	+4.7%	11.68	+28.4%
Total income	1,312.77	1,226.89	+7.0%	1,496.93	−12.3%
Profit before tax	327.09	226.73	+44.3%	551.94	−40.7%
Net profit for the period	275.68	196.02	+40.6%	453.64	−39.2%
EPS, basic (₹)	21.79	15.51	+40.5%	35.90	−39.3%
Net margin (%)	21.2	16.2		30.5

Consolidated

Filed with BSE: 07 Nov 2020, 15:41 IST
Board meeting: 07 Nov 2020
Period: 01 Jul 2020 to 30 Sep 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 07 Nov 2020, 15:41 IST
Board meeting: 07 Nov 2020
Period: 01 Jul 2020 to 30 Sep 2020
Review status: Unaudited
Source: XBRL filing on BSE